trial from the SFGM-TC and GFLLC for chronic lymphocytic leukemia: a multicenter, randomized, controlled Autologous stem cell transplantation as a first-line treatment strategy

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation.

  2011cited by this paper
• Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

  2010cited by this paper
• How I treat CLL up front.

  2010cited by this paper
• Chronic lymphocytic leukemia.

  2010cited by this paper
• Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial.

  2010cited by this paper
• Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.

  2010cited by this paper
• Improving survival in patients with chronic lymphocytic leukemia (1980-2008): the Hospital Clinic of Barcelona experience.

  2009cited by this paper
• Evaluating the impact of age and disease on survival of chronic lymphocytic leukaemia patients by a new method

  2009cited by this paper
• Stem cell transplantation in chronic lymphocytic leukemia.

  2009cited by this paper
• Improved survival in chronic lymphocytic leukemia in the past decade: a population-based study including 11,179 patients diagnosed between 1973–2003 in Sweden

  2009cited by this paper
• Chronic lymphocytic leukaemia.

  2008cited by this paper
• Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines.

  2008cited by this paper
• Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.

  2008cited by this paper
• Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia.

  2008cited by this paper
• Impact of rituximab and/or high-dose therapy with autotransplant at time of relapse in patients with follicular lymphoma: a GELA study.

  2008cited by this paper
• Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

  2007cited by this paper
• Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus

  2007cited by this paper
• Evaluation of Minimal Residual Disease in Blood and Bone Marrow for CLL as Assessed by 6 Color Flow Cytometry.

  2006cited by this paper
• High incidence of myelodysplasia and secondary leukaemia in the UK Medical Research Council Pilot of autografting in chronic lymphocytic leukaemia

  2006cited by this paper
• Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia.

  2005cited by this paper
• Results of the MRC pilot study show autografting for younger patients with chronic lymphocytic leukemia is safe and achieves a high percentage of molecular responses.

  2005cited by this paper
• Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival.

  2005cited by this paper
• Clinical significance of minimal residual disease, as assessed by different techniques, after stem cell transplantation for chronic lymphocytic leukemia.

  2005cited by this paper
• Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia.

  2005cited by this paper
• Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions.

  2004cited by this paper
• Impact of frontline fludarabine and cyclophosphamide combined treatment on peripheral blood stem cell mobilization in B-cell chronic lymphocytic leukemia.

  2004cited by this paper
• The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: a risk-matched analysis based on the VH gene mutational status.

  2004cited by this paper
• Successful CD34+ cell mobilization by intermediate-dose Ara-C in chronic lymphocytic leukemia patients treated with sequential fludarabine and Campath-1H

  2004cited by this paper
• Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia.

  2003cited by this paper
• Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

  2003cited by this paper
• Novel flow‐cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia

  2002cited by this paper
• Different clinical value of minimal residual disease after autologous and allogenic stem cell transplantation for chronic lymphocytic leukemia.

  2002cited by this paper
• Significance of the levels of bone marrow lymphoid infiltrate in chronic lymphocytic leukemia patients with nodular partial remission

  2002cited by this paper
• Monoclonal antibodies and autologous stem cell transplantation for lymphoma

  2001cited by this paper
• High-dose therapy and autologous stem-cell support for chemosensitive transformed low-grade follicular non-Hodgkin's lymphoma: a case-matched study from the European Bone Marrow Transplant Registry.

  2001cited by this paper
• Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.

  2001cited by this paper
• Genomic aberrations and survival in chronic lymphocytic leukemia.

  2000cited by this paper
• “Fludarabine Containing-Regimens May Adversely Affect Peripheral Blood Stem Cell Collection in Low-Grade Non Hodgkin Lymphoma Patients”

  2000cited by this paper
• Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.

  2000cited by this paper
• Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

  1999cited by this paper
• Clinical characteristics and outcome of young chronic lymphocytic leukemia patients: a single institution study of 204 cases.

  1999cited by this paper
• Autologous hematopoietic stem cell transplantation as salvage treatment for advanced B cell chronic lymphocytic leukemia

  1998cited by this paper
• Improvement of the chronic lymphocytic leukemia scoring system with the monoclonal antibody SN8 (CD79b).

  1997cited by this paper
• National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment.

  1996cited by this paper
• Proportional hazards tests and diagnostics based on weighted residuals

  1994cited by this paper
• Autologous and allogeneic bone marrow transplantation for chronic lymphocytic leukemia: preliminary results.

  1994cited by this paper
• Autologous and allogeneic bone marrow transplantation for poor prognosis patients with B-cell chronic lymphocytic leukemia.

  1993cited by this paper
• Treatment of relapsed non-Hodgkin's lymphomas with dexamethasone, high-dose cytarabine, and cisplatin before marrow transplantation.

  1991cited by this paper
• Presenting features and prognosis of chronic lymphocytic leukemia in younger adults.

  1991cited by this paper
• Autologous bone marrow transplantation in 69 patients with a history of low-grade B-cell non-Hodgkin's lymphoma.

  1991cited by this paper
• High-dose therapy and autologous bone marrow transplantation after failure of conventional chemotherapy in adults with intermediate-grade or high-grade non-Hodgkin's lymphoma.

  1987cited by this paper
• Testing for qualitative interactions between treatment effects and patient subsets.

  1985cited by this paper

• Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC.

  2011cites this paper